A open-label, global, multi-center Phase Ib clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IMDELLTRA and YL201 combination regimen in ES-SCLC patients
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Tarlatamab (Primary) ; YL 201 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- Sponsors Amgen
- 11 Oct 2024 New trial record
- 07 Oct 2024 According to a MediLink Therapeutics media release, the company announced a global clinical trial collaboration and supply agreement with Amgen Inc. Amgen will lead this trial and MediLink will provide the investigational drug YL201 for the combination study.